Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Other Non Operating Income (2019 - 2025)

BioNexus Gene Lab's Other Non Operating Income history spans 6 years, with the latest figure at $23476.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at $23476.0 for Q4 2025, down 96.52% from a year ago — trailing twelve months through Dec 2025 was $432117.0 (down 79.15% YoY), and the annual figure for FY2025 was $432117.0, down 79.15%.
  • Other Non Operating Income for Q4 2025 was $23476.0 at BioNexus Gene Lab, down from $107760.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $730105.0 in Q2 2024 to a low of -$208468.0 in Q1 2021.
  • The 4-year median for Other Non Operating Income is $91420.0 (2025), against an average of $169374.5.
  • The sharpest move saw Other Non Operating Income tumbled 122.95% in 2021, then soared 67.01% in 2022.
  • Year by year, Other Non Operating Income stood at $38930.0 in 2021, then plummeted by 276.67% to -$68776.0 in 2022, then soared by 1081.44% to $674994.0 in 2024, then tumbled by 96.52% to $23476.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $23476.0, $107760.0, and $209461.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.